Supplementary Figure 2: Introducing dendritic cell antibody internalization as an immunogenicity risk assessment tool
Supplemental Figure 2. FcgR Binding. Bococizumab and trastuzuamb were measured for binding to the low affinity FcgRIIA receptor, as compared to linking with the FRET probe. To confirm that the binding is Fc-related, the biotherapeutic/FRET pairs were incubated with anti-CD32 (Fc block).